公开(公告)号：US20250002471A1

公开(公告)日：2025-01-02

申请号：US18268469

申请日：2021-12-21

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Scott E. Lazerwith ,  Daniel G. Shore

IPC: C07D401/14 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/551 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D495/04 ,  C07D498/10

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US12091420B2

公开(公告)日：2024-09-17

申请号：US18376159

申请日：2023-10-03

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Xinpei Cai ,  Eda Y. Canales ,  Weng K. Chang ,  Gregory F. Chin ,  Henok H. Kinfe ,  Jessica L. Mckinley ,  Michael R. Mish ,  Devan Naduthambi ,  Jason K. Perry ,  Kevin X. Rodriguez ,  Scott D. Schroeder ,  Christopher J. Swank ,  Joshua J. Van Veldhuizen

IPC: C07D495/04 ,  C07D401/04 ,  C07D519/00

CPC classification number: C07D495/04 ,  C07D401/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula I:




and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

公开(公告)号：US20240239807A1

公开(公告)日：2024-07-18

申请号：US18365919

申请日：2023-08-04

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Xinpei Cai ,  Eda Y. Canales ,  Weng K. Chang ,  Gregory F. Chin ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Jessica L. McKinley ,  Michael R. Mish ,  Devan Naduthambi ,  Jason K. Perry ,  Kevin X. Rodriguez ,  Scott D. Schroeder ,  Christopher J. Swank ,  Joshua J. Van Veldhuizen

IPC: C07D495/04 ,  A61P31/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D491/113 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D495/04 ,  A61P31/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D491/113 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula I:




and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

公开(公告)号：US20250042915A1

公开(公告)日：2025-02-06

申请号：US18743475

申请日：2024-06-14

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Xinpei Cai ,  Eda Y. Canales ,  Weng K. Chang ,  Gregory F. Chin ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Jessica L. McKinley ,  Michael R. Mish ,  Devan Naduthambi ,  Jason K. Perry ,  Kevin X. Rodriguez ,  Scott D. Schroeder ,  Christopher J. Swank ,  Joshua J. Van Veldhuizen

IPC: C07D495/04 ,  A61P31/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D491/113 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

公开(公告)号：US11976083B2

公开(公告)日：2024-05-07

申请号：US17242617

申请日：2021-04-28

Applicant: Gilead Sciences, Inc.

Inventor： Eda Y. Canales ,  Weng K. Chang ,  Laurent P. Debien ,  Petr Jansa ,  Jennifer A. Loyer-Drew ,  Luisruben P. Martinez ,  Stephane Perreault ,  Gary B Phillips ,  Hyung-Jung Pyun ,  Roland D. Saito ,  Michael S. Sangi ,  Adam J. Schrier ,  Marina E. Shatskikh ,  James G. Taylor ,  Jennifer A. Treiberg ,  Joshua J. Van Veldhuizen

IPC: C07D471/18 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/437 ,  A61K45/06 ,  A61P3/10 ,  A61P7/02 ,  A61P19/02 ,  A61P35/00 ,  C07D471/12 ,  C07D471/14 ,  C07D487/08 ,  C07D491/22 ,  C07D498/18 ,  C07D498/22 ,  C07D513/18 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61K45/06 ,  C07D471/14

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

公开(公告)号：US20240116946A1

公开(公告)日：2024-04-11

申请号：US18376159

申请日：2023-10-03

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Xinpei Cai ,  Eda Y. Canales ,  Weng K. Chang ,  Gregory F. Chin ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Jessica L. McKinley ,  Michael R. Mish ,  Devan Naduthambi ,  Jason K. Perry ,  Kevin X. Rodriguez ,  Scott D. Schroeder ,  Christopher J. Swank ,  Joshua J. Van Veldhuizen

IPC: C07D495/04 ,  C07D401/04 ,  C07D519/00

CPC classification number: C07D495/04 ,  C07D401/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula I:




and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

公开(公告)号：US20240217990A1

公开(公告)日：2024-07-04

申请号：US18264670

申请日：2022-02-08

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Julian A. Codelli ,  Lan Jiang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Scott D. Schroeder ,  Daniel G. Shore

IPC: C07D519/00 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US20230365594A1

公开(公告)日：2023-11-16

申请号：US18180438

申请日：2023-03-08

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Yasamin Moazami ,  Scott D. Schroeder ,  Daniel G. Shore ,  Christopher J. Swank

IPC: C07D519/00 ,  C07D495/04

CPC classification number: C07D519/00 ,  C07D495/04

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US11661431B2

公开(公告)日：2023-05-30

申请号：US17721636

申请日：2022-04-15

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Yasamin Moazami ,  Scott D. Schroeder ,  Daniel G. Shore ,  Christopher J. Swank

IPC: C07D519/00 ,  C07D495/04 ,  A61P29/00

CPC classification number: C07D519/00 ,  C07D495/04

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US20250049780A1

公开(公告)日：2025-02-13

申请号：US18771751

申请日：2024-07-12

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Yasamin Moazami ,  Scott D. Schroeder ,  Daniel G. Shore

IPC: A61K31/4545 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.